Allarity Therapeutics (NASDAQ:ALLR) Posts Earnings Results, Beats Expectations By $0.04 EPS

Allarity Therapeutics (NASDAQ:ALLR) posted its quarterly earnings data on Friday. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04, FiscalAI reports.

Allarity Therapeutics Trading Up 0.7%

ALLR traded up $0.01 on Friday, hitting $1.37. 45,504 shares of the company’s stock were exchanged, compared to its average volume of 163,932. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.35. The stock has a market cap of $21.80 million, a price-to-earnings ratio of -1.90 and a beta of 0.51. The firm has a 50-day moving average price of $1.31 and a 200-day moving average price of $1.26.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ALLR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Finally, Ascendiant Capital Markets boosted their target price on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALLR. Private Advisor Group LLC purchased a new stake in shares of Allarity Therapeutics in the third quarter valued at approximately $441,000. Renaissance Technologies LLC lifted its position in Allarity Therapeutics by 274.1% during the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after buying an additional 181,426 shares in the last quarter. DRW Securities LLC acquired a new position in Allarity Therapeutics during the fourth quarter worth $133,000. Citadel Advisors LLC acquired a new position in Allarity Therapeutics during the third quarter worth $149,000. Finally, XTX Topco Ltd purchased a new stake in Allarity Therapeutics in the 2nd quarter valued at $51,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.